AKT3 Overexpression

CI-VAR-00003171Explore in graph →CIViC 1301

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm2
AKT3 Overexpression	Akt Inhibitor MK2206	Predictive	D	Supports Resistance	4	accepted	EID1922 Upregulation of AKT3 due to epigenetic reprogramming may confer acquired resistance to AKT inhibitor (MK2206) in breast cancer preclinical model. PMID 27297869 · Stottrup et al., 2016 · Open in CIViC	civic
AKT3 Overexpression	Pan-AKT Kinase Inhibitor GSK690693	Predictive	D	Supports Resistance	3	submitted	EID3001 Overexpression of AKT3 in lumenal breast cancer cell line SKBR3, which does not express the AKT3 isoform, induced a statistically significant 2.7 fold increase in IC50 for pan-AKT inhibitor GSK690693.… (full text at CIViC) PMID 24335962 · Chin et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Melanoma1
AKT3 Overexpression	Vemurafenib	Predictive	D	Supports Resistance	2	accepted	EID6261 An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-expres… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

Triple-Negative Breast Carcinoma1
AKT3 Overexpression	Pan-AKT Kinase Inhibitor GSK690693	Predictive	E	Supports Sensitivity Response	4	accepted	EID1923 AKT3 was found to be preferentially required for the proliferation and tumor growth of TNBC. It was found to be upregulated in a set of TNBC cell lines compared to other breast cancer types. Depletion… (full text at CIViC) PMID 24335962 · Chin et al., 2014 · Open in CIViC	civic